These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26433699)

  • 1. [Cost-efficacy of new antiviral treatments for chronic hepatitis C].
    Lens S; Bonacci M
    Aten Primaria; 2015 Oct; 47(8):479-81. PubMed ID: 26433699
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cure for the high cost of hepatitis C virus treatment.
    Etzion O; Ghany MG
    Ann Intern Med; 2015 May; 162(9):660-1. PubMed ID: 25820765
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-alpha for chronic hepatitis C: reducing the uncertainties.
    Koff RS
    Ann Intern Med; 1997 Nov; 127(10):918-20. PubMed ID: 9382371
    [No Abstract]   [Full Text] [Related]  

  • 5. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau NS; Jensen DM
    Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
    [No Abstract]   [Full Text] [Related]  

  • 6. 'HepConomics': cost-effective, indeed, but how can we pay for it?
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why We Should Be Willing to Pay for Hepatitis C Treatment.
    Chhatwal J; Chen Q; Kanwal F
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1711-3. PubMed ID: 26091736
    [No Abstract]   [Full Text] [Related]  

  • 9. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
    Koff RS
    J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of interferon treatment for hepatitis C.
    van Leeuwen DJ
    JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Bernstein D
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559948
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Dore GJ; Thein HH
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559947
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
    Kim WR; Poterucha JJ; Gross JB
    Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of interferon treatment for hepatitis C.
    Henley E
    JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
    [No Abstract]   [Full Text] [Related]  

  • 18. It's time to end insurance restrictions on life-saving hepatitis C treatments.
    Clary R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
    Mar J; Mar-Barrutia L; Gimeno-Ballester V; San Miguel R
    Med Clin (Barc); 2016 Jan; 146(2):61-4. PubMed ID: 26654558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.